AD/PD 2024 | ALZ-801 Phase II data & launch of Phase III study in early Alzheimer’s disease

John Hey, PhD, Alzheon, Inc., Framingham, MA, provides an update on the results of the open-label Phase II trial (NCT04693520) evaluating the effects of ALZ-801 on plasma biomarkers in APOE4 carriers with early Alzheimer’s disease (AD). ALZ-801 is an oral small molecule inhibitor of amyloid oligomer formation, designed to modify the neurodegenerative progression of AD. In this study, administration twice daily over a 2-year period produced a significant, sustained reduction in plasma p-tau181. In addition to this, the APOE4 heterozygous and homozygous population exhibited slowed hippocampal atrophy when compared to an external control group. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.